You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Article metrics

Article menu
Commentary
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

 

Online download statistics by month:

Online download statistics by month: January 2022 to August 2025

AbstractFullPdf
Jan 202268709
Feb 2022289299110
Mar 202213013381
Apr 202214215370
May 20229910343
Jun 202210210753
Jul 202212813028
Aug 202211912337
Sep 202211011031
Oct 202212613460
Nov 202212812843
Dec 2022868621
Jan 2023899134
Feb 202313813840
Mar 2023646519
Apr 2023586040
May 2023585944
Jun 2023393929
Jul 2023474834
Aug 2023525432
Sep 2023666637
Oct 2023515331
Nov 2023747544
Dec 2023929442
Jan 2024555524
Feb 2024565625
Mar 2024646559
Apr 2024787846
May 202411011133
Jun 2024646449
Jul 2024717231
Aug 2024363525
Sep 2024606029
Oct 2024747437
Nov 2024646625
Dec 2024727340
Jan 2025595939
Feb 2025222227
Mar 2025363648
Apr 2025798051
May 2025353638
Jun 2025313137
Jul 2025220
Aug 2025110
Total342434941675